RxDoctor Payments Data

Brian Hale, MD

Urology · Palm Harbor, FLNPI 1457355059

Payments from drug & device makers

$5,187in general payments, 2019–2025

Across 224 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$479
  • AbbVie$460
  • Sumitomo Pharma America, Inc.$306
  • Myriad Genetic Laboratories, Inc.$251
  • Procept Biorobotics Corporation$231
  • Astellas Pharma US Inc$228
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,10098%
  • Education$872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,187 in reported general payments places this provider in the 55th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$421,775
Medicare patients
755
Services billed
9,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide57$804,712
MyrbetriqMirabegron81$86,633
GemtesaVibegron55$37,152
Silodosin121$12,425
Dutasteride195$8,493
Tamsulosin Hcl741$8,342
Alfuzosin Hcl ErAlfuzosin Hcl380$7,859
Finasteride515$6,792
Tadalafil16$4,624
Testosterone26$4,452
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl27$2,859
Solifenacin Succinate76$2,351
Estradiol31$1,905
Oxybutynin Chloride118$1,886
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst108$1,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$228$891,345138 claims
Sumitomo Pharma America, Inc.Gemtesa$306$37,15255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 935 urology providers in Florida.

Other urology in Palm Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →